The expression of mutated forms of these genes is mostly absent in p/dCCA and HCC [32], thus IDH1/2 mutations could potentially be considered not only a therapeutic target for iCCA, but also a putative biomarker useful from a diagnostic perspective. This evidence concerns the gene PRRT2 and hepatocellular carcinoma.